Catalyst Pharmaceuticals Inc (CPRX)

May 09, 2025

Catalyst pharmaceuticals reaffirms 2025 revenue guidance of $545M-$565M with strong FIRDAPSE and AGAMREE performance - MSN

May 09, 2025

May 09, 2025

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 09, 2025

May 09, 2025

Catalyst Pharmaceuticals Reports Record Q1 2025 Results - TipRanks

May 09, 2025

May 09, 2025

Catalyst Pharmaceuticals Inc (CPRX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance

May 09, 2025

May 08, 2025

Catalyst Pharmaceuticals Q1 Earnings Beat, Firdapse Revenues Rise Y/Y - Zacks Investment Research

May 08, 2025

May 08, 2025

Earnings call transcript: Catalyst Pharmaceuticals Q1 2025 earnings beat fails to impress market - Investing.com

May 08, 2025

May 07, 2025

Catalyst Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 07, 2025

May 07, 2025

Catalyst Pharmaceutical (CPRX) Q1 Earnings and Revenues Top Estimates - Yahoo Finance

May 07, 2025

May 07, 2025

Catalyst Pharmaceuticals (CPRX) Exceeds Q1 Revenue Expectations | CPRX Stock News - GuruFocus

May 07, 2025

May 07, 2025

Catalyst Pharma Reports Record Q1 2025 Financial Results - TipRanks

May 07, 2025

May 07, 2025

Earnings Flash (CPRX) Catalyst Pharmaceuticals Reports Q1 Revenue $141.4M, vs. FactSet Est of $131.5M - marketscreener.com

May 07, 2025

May 07, 2025

Catalyst Pharmaceuticals Reports Record First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 07, 2025

May 07, 2025

Catalyst Pharmaceuticals Inc (CPRX) Q1 2025: Everything You Need To Know Ahead Of Earnings - GuruFocus

May 07, 2025

May 03, 2025

BlackRock, Inc. Reduces Stake in Catalyst Pharmaceuticals Inc - GuruFocus

May 03, 2025

Apr 30, 2025

Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Apr 30, 2025

Apr 30, 2025

Catalyst Pharmaceuticals to Participate in the BofA Securities H - GuruFocus

Apr 30, 2025

Apr 30, 2025

Catalyst Pharmaceuticals to Participate in the BofA Securities Health Care Conference 2025 - The Manila Times

Apr 30, 2025

Apr 30, 2025

Is Now The Time To Put Catalyst Pharmaceuticals (NASDAQ:CPRX) On Your Watchlist? - Yahoo

Apr 30, 2025

Apr 30, 2025

Catalyst Pharmaceuticals Leadership Team to Share Rare Disease Strategy at Major BofA Healthcare Conference - Stock Titan

Apr 30, 2025

Apr 28, 2025

Catalyst Pharmaceuticals (NASDAQ:CPRX) stock performs better than its underlying earnings growth over last five years - simplywall.st

Apr 28, 2025

Apr 27, 2025

Catalyst Pharmaceuticals, Inc. (CPRX): Among Stocks with Consistent Growth to Buy Now - MSN

Apr 27, 2025

Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025

Apr 25, 2025

Catalyst Pharmaceuticals Inc. stock rises Friday, still underperforms market - MarketWatch

Apr 25, 2025

Apr 22, 2025

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 | CPRX Stock News - GuruFocus

Apr 22, 2025

Apr 22, 2025

Catalyst Pharmaceuticals to Release First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025 - Nasdaq

Apr 22, 2025

Apr 22, 2025

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 - GlobeNewswire

Apr 22, 2025

Apr 21, 2025

BofA Adjusts Price Target on Catalyst Pharmaceuticals to $34 From $33 - marketscreener.com

Apr 21, 2025

Apr 21, 2025

Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from Bof - GuruFocus

Apr 21, 2025

Apr 21, 2025

Catalyst Pharmaceuticals (CPRX) Sees Price Target Boost from BofA to $34 | CPRX Stock News - GuruFocus

Apr 21, 2025

Apr 17, 2025

Catalyst Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors despite daily gains - MarketWatch

Apr 17, 2025

Apr 15, 2025

Catalyst Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch

Apr 15, 2025

Apr 11, 2025

Is Catalyst Pharmaceuticals, Inc. (CPRX) the Best Russell 2000 Stock to Buy According to Wall Street Analysts? - MSN

Apr 11, 2025

Apr 11, 2025

11 Best Russell 2000 Stocks to Buy According to Wall Street Analysts - Insider Monkey

Apr 11, 2025

Apr 09, 2025

Catalyst Pharmaceuticals (NasdaqCM:CPRX) Navigates Market Volatility With 3% Dip - Yahoo Finance

Apr 09, 2025

Apr 09, 2025

New Drug Submission for AGAMREE® (vamorolone) Accepted for Priority Review by Health Canada for the Treatment of Duchenne Muscular Dystrophy - BioSpace

Apr 09, 2025

Apr 08, 2025

Catalyst Says Health Canada Accepts New Drug Submission for Potential Neuromuscular Disease Treatment - marketscreener.com

Apr 08, 2025

Apr 08, 2025

Catalyst Pharmaceuticals Announces Health Canada’s - GlobeNewswire

Apr 08, 2025

Apr 08, 2025

First DMD Treatment Could Reach Canada as AGAMREE Receives Priority Review Status - Stock Titan

Apr 08, 2025

Apr 07, 2025

Lambert Eaton Myasthenic Syndrome Market 2025: Growth, - openPR.com

Apr 07, 2025

Apr 03, 2025

Why a Clutch of Pharmaceutical and Biotech Stocks Escaped the Market's Swoon on Thursday - Yahoo Finance

Apr 03, 2025

Apr 02, 2025

What Makes Catalyst Pharmaceuticals (CPRX) an Investment Choice? - MSN

Apr 02, 2025

Apr 02, 2025

Prudential Financial Inc. Buys 128,525 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Apr 02, 2025

Apr 01, 2025

Catalyst Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch

Apr 01, 2025

Mar 31, 2025

Catalyst Pharmaceuticals Inc. stock underperforms Monday when compared to competitors - MarketWatch

Mar 31, 2025

Mar 31, 2025

Cornercap Investment Counsel Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat

Mar 31, 2025

Mar 28, 2025

Catalyst (CPRX) Up 14.7% Since Last Earnings Report: Can It Continue? - Yahoo Finance

Mar 28, 2025

Mar 27, 2025

Jim Cramer on Catalyst Pharmaceuticals (CPRX): ‘That’s My Kind of Stock!’ - MSN

Mar 27, 2025